Pfizer’s Finance Leader Moves to Consumer Goods

The U. S. drugmaker announced that its chief financial officer, Dave Denton, will leave the company on August 15 to pursue a new opportunity in the consumer goods sector. The move follows Denton’s appointment as Pfizer’s finance head in 2022, after experience at CVS and Lowe’s. Cecile Guegan, who runs finance for Pfizer’s global biopharmaceutical division, will step in as interim CFO from August 16. She is expected to guide the firm through the transition period while a permanent successor is sought both internally and externally.Dentons tenure at Pfizer saw the company complete several high‑profile acquisitions, including Seagen, Biohaven, and Metsera. These deals were part of a strategy to broaden Pfizer’s portfolio in oncology, neurology, and obesity treatment. The announcement sent a slight dip to Pfizer’s stock, with shares falling 1. 6% in pre‑market trading. Investors will be watching how the company maintains financial stability during this leadership change. Pfizer’s CEO, Albert Bourla, praised Denton for his role in steering the company through complex transactions. The firm emphasized that both Denton and Guegan will collaborate closely to ensure a smooth handover of responsibilities.